

MEDICAL REVIEW GUIDELINE

Faricimab-svoa Ophthalmic Criteria for Coverage



Vabysmo® (faricimab-svoa) Criteria for Coverage

Effective Date: 9/1/2024

Medical Care Management Committee Approval: 6/20/2024

Contents

Coverage Policy	1
Diagnosis, Specific Criteria	1
Continuation Criteria	Error! Bookmark not defined.
Applicable Codes	2
Policy Revision History	6

Coverage Policy

This Medical Review Guideline (Guideline) is provided for informational purposes only and does not constitute medical advice. It is intended solely for the use of Community Health Choice, Inc. (Community) clinical staff as a guideline for use in determining medical necessity of requested procedures, medications and therapy. This Guideline does not address eligibility or benefit coverage. Other Policies and Coverage Determination Guidelines may apply. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements and the plan benefit coverage prior to use of this Medical Review Guideline. If there is a discrepancy between this Guideline and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern. Community reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

This policy applies to the following Vabysmo® (faricimab-svoa) product:

HCPCS Code	Description	Maximum Dosage per Administration
J2777	Injection, faricimab-svoa, 0.1 mg	Faricimab-svoa 60 units (6 mg) per injection, per eye

Diagnosis Specific Criteria

Vabysmo® (faricimab-svoa) will be considered medically necessary for members meeting ALL of the following criteria:

1. Prescribed by or in consultation with an ophthalmologist or retinal specialist; AND
2. Age ≥18 years; AND
3. Diagnosis of one of the following; AND:
 - a. Neovascular (wet) age-related macular degeneration (AMD)
 - b. Macular edema following retinal vein occlusion (RVO)
 - c. Diabetic Macular Edema (DME)
4. History of inadequate response, adverse event or contraindication to intravitreal bevacizumab (may

MEDICAL REVIEW GUIDELINE

Faricimab-svoa Ophthalmic Criteria for Coverage



require authorization); AND

- a. EXCEPTION: diagnosis diabetic macular edema AND visual acuity is 20/50 or worse, then no trial of bevacizumab is required
5. Vabysmo® (faricimab-svoa) is prescribed as monotherapy, no other anti-VEGF medications used concomitantly

Criteria for Continuation of Coverage

1. Request is for same eye as initially approved; request for treatment of additional eye will be considered as an initial coverage request; AND
2. Vabysmo® (faricimab-svoa) is prescribed as monotherapy, no other anti-VEGF medications used concomitantly; AND
3. Meets diagnosis specific criteria; AND
4. Documentation of disease stabilization or improvement with use

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive.

HCPCS Code	Description
J2777	Injection, faricimab-svoa, 0.1 mg

Formatted Table

HCPCS Code	Description
E08.3111	Diabetes mellitus due to underlying condition diabetic retinopathy not otherwise specified with macular edema, right eye
E08.3112	Diabetes mellitus due to underlying condition diabetic retinopathy not otherwise specified with macular edema, left eye
E08.3113	Diabetes mellitus due to underlying condition diabetic retinopathy not otherwise specified with macular edema, bilateral
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral

MEDICAL REVIEW GUIDELINE

Faricimab-svoa Ophthalmic Criteria for Coverage



E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E08.37X1	Diabetes mellitus due to underlying condition diabetic retinopathy with macular edema resolved following treatment, right eye
E08.37X2	Diabetes mellitus due to underlying condition diabetic retinopathy with macular edema resolved following treatment, left eye
E08.37X3	Diabetes mellitus due to underlying condition diabetic retinopathy with macular edema resolved following treatment, bilateral
E09.3111	Drug-induced diabetes mellitus diabetic retinopathy not otherwise specified with macular edema, right eye
E09.3112	Drug-induced diabetes mellitus diabetic retinopathy not otherwise specified with macular edema, left eye
E09.3113	Drug-induced diabetes mellitus diabetic retinopathy not otherwise specified with macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E09.37X1	Drug-induced diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, right eye
E09.37X2	Drug-induced diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, left eye
E09.37X3	Drug-induced diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, bilateral
E10.3111	Type 1 diabetes mellitus with diabetic retinopathy not otherwise specified with macular edema, right eye
E10.3112	Type 1 diabetes mellitus with diabetic retinopathy not otherwise specified with macular edema, left eye
E10.3113	Type 1 diabetes mellitus with diabetic retinopathy not otherwise specified with macular edema, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

MEDICAL REVIEW GUIDELINE

Faricimab-svoa Ophthalmic Criteria for Coverage



E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.37X1	Type 1 diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, right eye
E10.37X2	Type 1 diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, left eye
E10.37X3	Type 1 diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, bilateral
E11.3111	Type 2 diabetes mellitus with diabetic retinopathy not otherwise specified with macular edema, right eye
E11.3112	Type 2 diabetes mellitus with diabetic retinopathy not otherwise specified with macular edema, left eye
E11.3113	Type 2 diabetes mellitus with diabetic retinopathy not otherwise specified with macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.37X1	Type 2 diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, right eye
E11.37X2	Type 2 diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, left eye
E11.37X3	Type 2 diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, bilateral
E13.3111	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema, right eye
E13.3112	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema, left eye

MEDICAL REVIEW GUIDELINE

Faricimab-svoa Ophthalmic Criteria for Coverage



E13.3113	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema, bilateral
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E13.37X1	Other specified diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, right eye
E13.37X2	Other specified diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, left eye
E13.37X3	Other specified diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, bilateral
E13.37X3	Other specified diabetes mellitus diabetic retinopathy with macular edema resolved following treatment, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8190	Central retinal vein occlusion, unspecified eye, with macular edema
H34.8191	Central retinal vein occlusion, unspecified eye, with retinal neovascularization
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar

MEDICAL REVIEW GUIDELINE

Faricimab-svoa Ophthalmic Criteria for Coverage



H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

Policy Revision History

Status	Effective Date	Description
Baseline	9/1/2024	Initial version of Vabysmo® (faricimab-svoa) Coverage Criteria Policy